Metabolic Syndrome and Psoriasis

Deep Dive

From a western clinical standpoint, psoriasis is no longer viewed as a skin‑limited disorder but as a systemic inflammatory disease that raises ... From a western clinical standpoint, psoriasis is no longer viewed as a skin‑limited disorder but as a systemic inflammatory disease that raises cardiometabolic risk. The same cytokine networks that drive psoriatic plaques—particularly TNF‑α and the IL‑23/IL‑17 axis—intersect with pathways that promote insulin resistance, endothelial dysfunction, and atherosclerosis. Adipose tissue is an active endocrine organ in this story; excess visceral fat secretes adipokines (leptin, resistin) and reduces adiponectin, amplifying Th17/TNF signaling and impairing insulin action. Physiologic studies show impaired flow‑mediated dilation and increased non‑calcified coronary plaque in psoriasis, supporting a vascular link. Epidemiology aligns with these mechanisms. Meta‑analyses report roughly 1.5–2.0‑fold higher odds of metabolic syndrome in psoriasis, with elevated risks for obesity, hypertension, dyslipidemia, and type 2 diabetes. Severity matters: more extensive or long‑standing disease tracks with greater metabolic burden and higher rates of myocardial infarction and major adverse cardiovascular events. While most data are observational and susceptible to confounding by lifestyle and treatment selection, the consistency and dose–response trends strengthen causal inference. These connections have practical consequences. Guidelines advise routine screening for blood pressure, BMI/waist circumference, fasting lipids, and glucose/HbA1c in adults with psoriasis—especially when disease is moderate‑to‑severe or accompanied by psoriatic arthritis. Co‑management with primary care/endocrinology/cardiology can help address risk. Lifestyle interventions—calorie reduction, Mediterranean‑style eating, physical activity, smoking cessation, and sleep optimization—offer dual benefits: they improve metabolic syndrome components and can reduce psoriasis severity and enhance therapeutic response. Medication choices also matter. Cyclosporine and systemic corticosteroids may worsen blood pressure, lipids, or glycemia; acitretin can raise triglycerides. Biologic agents that neutralize TNF‑α or IL‑23/IL‑17 reduce systemic inflammatory load, and observational data suggest potential cardiovascular benefit, though definitive randomized outcome trials are still needed. Metformin, statins, and GLP‑1 receptor agonists, when indicated for cardiometabolic disease, may confer ancillary improvements in skin disease. Research priorities include randomized trials measuring hard cardiovascular outcomes in biologic‑treated psoriasis, mechanistic studies of adipokines and endothelial repair, and pragmatic trials of integrated lifestyle programs tailored to psoriatic disease.